The study investigates long-term management of gender-affirming hormone treatment (GAHT) for transgender individuals, focusing on treatment adjustments, safety, and hormonal targets.
A large sample of transgender people (AFAB and AMAB) in Italy was monitored from 2005 to 2022, collecting various health data to analyze their GAHT experiences.
Findings reveal that transgender AFAB individuals reached hormone treatment goals sooner and more consistently, suggesting AMAB individuals may need more frequent follow-ups to improve their treatment outcomes.